CytoDyn (OTCMKTS:CYDY)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Friday.

Separately, ValuEngine raised CytoDyn from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th.

CytoDyn (CYDY) traded down $0.03 during midday trading on Friday, reaching $0.57. The company had a trading volume of 137,648 shares, compared to its average volume of 131,435. CytoDyn has a one year low of $0.46 and a one year high of $0.84.

CytoDyn (OTCMKTS:CYDY) last posted its quarterly earnings results on Tuesday, October 10th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). analysts anticipate that CytoDyn will post -0.19 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at

About CytoDyn

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

Receive News & Ratings for CytoDyn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc. and related companies with's FREE daily email newsletter.